What’s in EXICURE INC (OTCMKTS:XCUR) After Decline in Shorted Shares?

The stock of EXICURE INC (OTCMKTS:XCUR) registered a decrease of 0.19% in short interest. XCUR’s total short interest was 51,700 shares in July as published by FINRA. Its down 0.19% from 51,800 shares, reported previously. With 71,000 shares average volume, it will take short sellers 1 days to cover their XCUR’s short positions.

The stock increased 2.77% or $0.07 during the last trading session, reaching $2.6. About 11,735 shares traded. Exicure, Inc. (OTCMKTS:XCUR) has 0.00% since July 14, 2018 and is . It has underperformed by 4.43% the S&P500.

Exicure, Inc., a clinical stage biotechnology company, develops gene regulatory and immuno-oncology therapeutics based on spherical nucleic acid technology. The company has market cap of $115.36 million. The company's three clinical programs include AST-008, which is in a Phase I clinical trial, an SNA consisting of toll-like receptor 9 that is designed for immuno-oncology applications; XCUR17, which is in a Phase I clinical trial, an antisense SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha, a protein that helps in the initiation and maintenance of psoriasis; and AST-005, which is in a Phase I clinical trial, an SNA containing tumor necrosis factor antisense oligonucleotides. It currently has negative earnings. It is also developing SNAs that target IL-4RA mRNA for the treatment of atopic dermatitis; and marketing dupilumab, a human monoclonal antibody for treating moderate to severe atopic dermatitis in the United States.

Another recent and important Exicure, Inc. (OTCMKTS:XCUR) news was published by Seekingalpha.com which published an article titled: “Exicure, Inc. announces expected closing of ~$22M private placement offering – Seeking Alpha” on August 22, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.